These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 36056954)
1. Do female and male patients derive similar benefits from approved systemic oncology therapies? A systematic review and meta-analysis. Arciero V; McDonald E; Nguyen V; Saluja R; Raphael M; Parmar A; Chan KKW J Cancer Res Clin Oncol; 2023 Jul; 149(8):4215-4224. PubMed ID: 36056954 [TBL] [Abstract][Full Text] [Related]
2. Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis. Arciero VS; Cheng S; Mason R; McDonald E; Saluja R; Chan KKW Age Ageing; 2018 Sep; 47(5):654-660. PubMed ID: 29788041 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review. Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573 [TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
6. Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. Cheng S; Qureshi M; Pullenayegum E; Haynes A; Chan KK ESMO Open; 2017; 2(4):e000225. PubMed ID: 29209535 [TBL] [Abstract][Full Text] [Related]
7. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731 [TBL] [Abstract][Full Text] [Related]
9. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. Samuel JN; Booth CM; Eisenhauer E; Brundage M; Berry SR; Gyawali B JAMA Oncol; 2022 Jun; 8(6):879-886. PubMed ID: 35482347 [TBL] [Abstract][Full Text] [Related]
10. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002 [TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
12. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration. He Q; Li Q; Lv F; Kaitin KI; Shao L Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659 [TBL] [Abstract][Full Text] [Related]
13. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827 [TBL] [Abstract][Full Text] [Related]
14. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. Gyawali B; Hey SP; Kesselheim AS JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Santos FN; de Castria TB; Cruz MR; Riera R Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542 [TBL] [Abstract][Full Text] [Related]
16. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies. Rittberg R; Czaykowski P; Niraula S JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254 [TBL] [Abstract][Full Text] [Related]